Autoimmunity BioSolutions develops a future immuno-corrective treatment that restores healthy immune function.
Autoimmunity BioSolutions has raised $1.0M in total funding. The most recent round was Seed. The last funding was announced in May 2026.
Autoimmunity BioSolutions's investors include Alexandria Venture Investments, Eos BioInnovation, NewTech Investment Holdings, Independent Capital Management, Inc., Elmsted Partners LLC.
Autoimmunity BioSolutions is headquartered in Houston, United States.
Autoimmunity BioSolutions develops a future immuno-corrective treatment that restores healthy immune function.
Autoimmunity BioSolutions is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Autoimmunity BioSolutions — Funding & Investors." VCBacked, May 6, 2026, https://www.vcbacked.co/company/autoimmunity-biosolutions. Accessed October 29, 2026.
VCBacked. (2026). Autoimmunity BioSolutions — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/autoimmunity-biosolutions
{{cite web |title=Autoimmunity BioSolutions — Funding & Investors |url=https://www.vcbacked.co/company/autoimmunity-biosolutions |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated